NO20055880L - Memantin orale doseringsformer - Google Patents

Memantin orale doseringsformer

Info

Publication number
NO20055880L
NO20055880L NO20055880A NO20055880A NO20055880L NO 20055880 L NO20055880 L NO 20055880L NO 20055880 A NO20055880 A NO 20055880A NO 20055880 A NO20055880 A NO 20055880A NO 20055880 L NO20055880 L NO 20055880L
Authority
NO
Norway
Prior art keywords
memantine
dosage form
dosage forms
oral dosage
memantine oral
Prior art date
Application number
NO20055880A
Other languages
English (en)
Norwegian (no)
Inventor
Bruce A Firestone
John J Vander Zanden
Janet K Cheetham
Richard Kurjan
Teresa H Kuan
Ching-Ming Chang
J Abraham M Espiritu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20055880L publication Critical patent/NO20055880L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055880A 2003-06-16 2005-12-12 Memantin orale doseringsformer NO20055880L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16
PCT/US2004/018506 WO2004112768A1 (en) 2003-06-16 2004-06-10 Memantine oral dosage forms

Publications (1)

Publication Number Publication Date
NO20055880L true NO20055880L (no) 2005-12-28

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055880A NO20055880L (no) 2003-06-16 2005-12-12 Memantin orale doseringsformer

Country Status (16)

Country Link
US (2) US20040254251A1 (pt)
EP (1) EP1631273A1 (pt)
JP (1) JP2006527774A (pt)
KR (1) KR20060033727A (pt)
CN (1) CN1805737A (pt)
AU (1) AU2004249151A1 (pt)
BR (1) BRPI0411451A (pt)
CA (1) CA2529535A1 (pt)
IL (1) IL172233A0 (pt)
MX (1) MXPA05012810A (pt)
NO (1) NO20055880L (pt)
PL (1) PL378902A1 (pt)
RU (1) RU2006101225A (pt)
TW (1) TW200524639A (pt)
WO (1) WO2004112768A1 (pt)
ZA (1) ZA200509379B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
AU2007215005A1 (en) * 2006-02-10 2007-08-23 Janssen Pharmaceutica N.V. Novel tricyclic dihydropyrazines as potassium channel openers
JP4981036B2 (ja) * 2006-04-20 2012-07-18 伊藤ハム株式会社 コンフォメーション病医薬組成物
WO2008005036A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
BR112014026292B1 (pt) * 2012-04-24 2022-09-27 Daiichi Sankyo Company, Limited Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
MXPA05012810A (es) 2006-02-13
PL378902A1 (pl) 2006-05-29
TW200524639A (en) 2005-08-01
BRPI0411451A (pt) 2006-07-18
RU2006101225A (ru) 2006-06-10
CN1805737A (zh) 2006-07-19
WO2004112768A1 (en) 2004-12-29
IL172233A0 (en) 2006-04-10
EP1631273A1 (en) 2006-03-08
US20060251717A1 (en) 2006-11-09
JP2006527774A (ja) 2006-12-07
US20040254251A1 (en) 2004-12-16
CA2529535A1 (en) 2004-12-29
KR20060033727A (ko) 2006-04-19
ZA200509379B (en) 2006-11-29
AU2004249151A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
NO20055880L (no) Memantin orale doseringsformer
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
AR050418A1 (es) Dosificacion fija de anticuerpos her
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR0015188A (pt) Composições farmacêuticas
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
KR970061244A (ko) 치매 치료용 약학 조성물
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
AR036312A1 (es) Composicion farmaceutica
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
KR970025615A (ko) 암 전이 억제제
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
MXPA03003994A (es) Composiciones de metformina de liberacion controlada.
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
EA200800075A1 (ru) Схема дозирования для празугреля
SE0102887D0 (sv) New formulation
US5026706A (en) Method for treating dysuria using naftopidil
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application